Use of sodium D, L-3-hydroxybutyrate as adjunct therapy in two siblings with HMG-CoA lyase deficiency

Abstract

3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency is a rare autosomal recessive mitochondrial disease characterised by recurrent life-threatening metabolic crises generally presenting in neonates or infancy during catabolic stress triggered by prolonged fasting or intercurrent illness. Acute decompensations with lethargy, vomiting, hypoketotic hypoglycemia and metabolic acidosis may evolve into Reye-like syndrome if untreated, with acute liver failure, hyperammonemic encephalopathy, dilated cardiomyopathy, and death in 20% of cases. Long-term health complications include psychomotor retardation, white matter abnormalities, epilepsy, hepatic steatosis, pancreatitis, cardiomyopathy, and arrythmia. The mitochondrial enzyme catalyses the cleavage of HMG-CoA to acetyl-CoA and acetoacetate, the common final step of ketogenesis and leucine degradation, resulting in diagnostic urinary organic acid pattern (elevated 3-hydroxy-3-methylglutaric, 3-methylgutaconic, 3-methylglutaric, and 3-hydroxyisovaleric acids) with the absence of ketonuria, when deficient. Therapeutic interventions include dietary protein or leucine and fat restriction, carnitine supplementation, avoidance of fasting, and use of carbohydrate-based high caloric intake when unwell. We describe the clinical course and diagnostic work-up in two affected siblings, with the proband presenting with severe neonatal onset disease with metabolic acidosis, non-ketotic hypoglycaemia, hyperammonemia and white matter changes on brain MRI. High-risk screening for a younger sibling led to pre-emptive management with good outcomes. Sodium D, L-3-hydroxybutyrate (S-DL-3OHB) was used in both siblings as an adjunct therapy to prevent cerebral dysfunction and cardiomyopathy, with the rationale that decreased ketogenesis in this disorder may impact the major energy source for the brain and heart during starvation. S-DL-3OHB therapy is a well-tolerated and effective therapeutic option for this disorder.

Keywords

HMG-CoA lyase deficiency / mitochondrial enzyme / 3-Hydroxy-3-methylglutaric aciduria / defect in ketogenesis / metabolic crises / sodium D / L-3-hydroxybutyrate

References

[1] GrunertSC.3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: one disease - many faces.Orphanet J Rare Dis2020;15:48 PMCID:PMC7023732

[2] AlfadhelM,AlSaif S.Expanded newborn screening program in Saudi Arabia: incidence of screened disorders.J Paediatr Child Health2017;53:585-91

[3] SantarelliF,EneaA.A neonatal case of 3-hydroxy-3-methylglutaric-coenzyme A lyase deficiency.Ital J Pediatr2013;39:33 PMCID:PMC3685558

[4] ThompsonS,SelvanathanA.Treatment of HMG-CoA lyase deficiency-longitudinal data on clinical and nutritional management of 10 Australian cases.Nutrients2023;15:531 PMCID:PMC9920477

[5] PieJ,PuisacB.Molecular genetics of HMG-CoA lyase deficiency.Mol Genet Metab2007;92:198-209

[6] MorrisAA.Cerebral ketone body metabolism.J Inherit Metab Dis2005;28:109-21

[7] HuemerM,Wandl-VergesslichK,WandersRJ.Stroke-like encephalopathy in an infant with 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency.Eur J Pediatr1998;157:743-6

[8] StaceyTE,TraceyBM.Dizygotic twins with 3-hydroxy-3-methylglutaric aciduria; unusual presentation, family studies and dietary management.Eur J Pediatr1985;144:177-81

[9] AlfadhelM,AlmaghthawiH.HMG-CoA lyase deficiency: a retrospective study of 62 saudi patients.Front Genet2022;13:880464 PMCID:PMC9136170

[10] YalcinkayaC,GunduzE,KocerN.MRI and MRS in HMG-CoA lyase deficiency.Pediatr Neurol1999;20:375-80

[11] SassJO,MitchellGA.Inborn errors of ketone body metabolism and transport: an update for the clinic and for clinical laboratories.J Inborn Errors Metabolism Scr2018;6:2326409818771101

[12] BhattacharyaK,TolunAA.The use of sodium DL-3-hydroxybutyrate in severe acute neuro-metabolic compromise in patients with inherited ketone body synthetic disorders.Orphanet J Rare Dis2020;15:53 PMCID:PMC7029565

[13] DalkeithT,ThompsonS. The use of 3-hydroxybutyrate in patients with fat oxidation disorders. In 12th International Congress of Inborn Errors of Metabolism. Barcelona, Spain; 2013.

[14] FrançoisB,SchutgensRBH.Glucose metabolism in a child with 3-hydroxy-3-methylglutaryl-coenzyme a lyase deficiency.J Inherit Metab Dis1981;4:163-4

[15] RichardsS,BaleS.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology.Genet Med2015;17:405-24 PMCID:PMC4544753

[16] ChalmersRA. Organic acids in man: analytical chemistry, biochemistry and diagnosis of the organic acidurias. Dordrecht: Springer; 2012. Available from: https://link.springer.com/book/10.1007/978-94-009-5778-7 [Last accessed on 16 Sep 2023].

[17] GoodmanSI.Diagnosis of organic acidemias by gas chromatography-mass spectrometry.Lab Res Methods Biol Med1981;6:1-158

[18] MillingtonDS,NorwoodDL.Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism.J Inherit Metab Dis1990;13:321-4

[19] DevanapalliB,CarpenterK. D, L-3-hydroxybutyrate treatment of HMG-CoA lyase deficiency in a patient. In 13th International Congress of Inborn Errors of Metabolism. Rio de Janeiro, Brazil; 2017.

[20] GautschiM,SlotboomJ,ZurcherT.Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy.Pediatr Res2015;77:91-8

[21] HabarouF,LebigotE.Ketone bodies as a possible adjuvant to ketogenic diet in PDHc deficiency but not in GLUT1 deficiency.JIMD Rep2018;38:53-9 PMCID:PMC5874212

[22] VanHove JL,JaekenJ.D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD).Lancet2003;361:1433-5

[23] VanRijt WJ,duMarchie Sarvaas GJ.Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD.Pediatrics2014;134:e1224-8

[24] vanRijt WJ,AllersmaDP.Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency.Genet Med2020;22:908-16 PMCID:PMC7200590

[25] PleckoB,SchoberE.Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy.Pediatr Res2002;52:301-6

[26] FischerT,MarquardtT.Long-term ketone body therapy of severe multiple acyl-CoA dehydrogenase deficiency: a case report.Nutrition2019;60:122-8

[27] BougneresPF,FerreP.Ketone body transport in the human neonate and infant.J Clin Invest1986;77:42-8 PMCID:PMC423306